Oct. 3 at 6:27 PM
$INO Last Jan, PGEN estimated the RRP market in the US to be 27,000 adults. They'll have at least a year head start on INO, so what % of the market does INO estimate 3107 will get? What will 3107 cost per patient? Has INO management ever issued a business case and path to profitability? Y'all think submitting a BLA or getting FDA approval will send the stock soaring, but PGEN was
$1.80 at approval and it's
$3.20 now.
